Previous studies carried out in vitro have demonstrated induction of PRDXs via the Nrf2/Keap1 pathway [28], but there are no reports on Nrf2 or Keap1 in clinical breast cancer material. This evidence concerns the gene NFE2L2 and breast carcinoma.